NCT06626412Active, not recruiting
Longitudinal SV2A PET and MRI in Premanifest HD
Longitudinal Imaging of Striatal Synaptic Density and Volume in People With Premanifest Huntington's Disease.
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
AIM: to compare the sensitivity of SV2A PET and volumetric MRI to detect longitudinal striatal changes in premanifest HD. DESIGN: The investigators will include late premanifest HD mutations carriers and matched healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 18F-SynVesT-1 PET and volumetric MRI at baseline and after 2 years.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 4 Dec 2024
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Diseases
- Huntington's disease
- NCT number
- NCT06626412
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 4 Dec 2024 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
Other illness
- neuropsychiatric diseases (other than HD for HD mutation carriers)
- major internal medical diseases
- history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
Other
- white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
- contraindications for MR
- pregnancy
Who the study is looking for
- Age 20-75 years inclusive.
- Capacity to understand the informed consent form.
- HD mutation carriers:
- HTT (CAG)n ≥ 40
- HD-ISS \< 2
- CAP100 score \> 70
Age in the registry: 20 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.